Alpha 2.0
Login Register
» Authors » Lars Viktrup

Lars Viktrup

Explore the profile of Lars Viktrup including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 107
Citations 1549
Followers 0
Related Specialties
Urology
General Medicine
Rheumatology
Top 10 Co-Authors
Christine R West
Mark T Brown
Kenneth M Verburg
Thomas J Schnitzer
Claus G Roehrborn
Joseph C Cappelleri
Andrew G Bushmakin
Leslie Tive
Francis Berenbaum
Philip G Conaghan
Published In
Eur Urol
Curr Med Res Opin
J Urol
Int J Urol
BJU Int
Affiliations
Soon will be listed here.
Recent Articles
1.
Stigmatizing attitudes toward people with migraine by people without active migraine: results of the OVERCOME (US) study
Shapiro R, Viktrup L, Muenzel E, Buse D, Zagar A, Ashina S, et al.
BMC Neurol . 2025 Mar; 25(1):103. PMID: 40075330
Background: Migraine is associated with various types of stigma. This study aims to evaluate stigmatizing attitudes towards people with migraine by people without active migraine. Methods: OVERCOME (US) was a...
2.
Treatment Patterns and Healthcare Resource Utilization by Gender and Migraine Frequency in Adult Patients Receiving Galcanezumab Versus Standard of Care Preventive Medications Over 24 months: A United States Retrospective Claims Study
Varnado O, Vu M, Buysman E, Kim G, Allenback G, Hoyt M, et al.
Patient Prefer Adherence . 2025 Mar; 19:543-567. PMID: 40046564
Objective: To describe 24-month treatment patterns, healthcare resource utilization (HCRU), and direct costs of patients initiating galcanezumab (GMB) versus standard of care migraine preventive medications (SOC), stratified by gender and...
3.
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Lampl C, Seng E, Vincent M, Lenderking W, Hoyt M, Hetherington L, et al.
J Headache Pain . 2024 Dec; 25(1):220. PMID: 39695402
Background: The total burden of migraine includes not only the episodes with headache pain but extends throughout the interictal periods. Interictal symptoms and associated psychological responses may profoundly impact well-being...
4.
Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis
Kim G, Hoyt M, Zakharyan A, Durica J, Wallem A, Viktrup L
Adv Ther . 2024 Dec; 42(2):918-934. PMID: 39680312
Introduction: To date, no study has compared the healthcare resource utilization (HCRU), costs, and discontinuation of the two calcitonin gene-related peptide antagonists, galcanezumab (monoclonal antibody subcutaneously injected monthly) and rimegepant...
5.
Patients' Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)
Seng E, Lampl C, Viktrup L, Lenderking W, Karn H, Hoyt M, et al.
Pain Ther . 2024 Sep; 13(6):1589-1615. PMID: 39298053
Introduction: Migraine is under-diagnosed and under-treated. Many people with migraine do not seek medical care, and those who do may initially receive a different diagnosis and/or be dissatisfied with provided...
6.
Health care resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States
Varnado O, Vu M, Buysman E, Kim G, Allenback G, Hoyt M, et al.
J Manag Care Spec Pharm . 2024 Aug; 30(8):792-804. PMID: 39088336
Background: Health care resource utilization (HCRU) and direct costs incurred over 12 months following initiation of galcanezumab (GMB) or standard-of-care (SOC) preventive migraine treatments have been evaluated. However, a gap...
7.
A 3-year follow-up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims-based cohort study in the United States
Joshi S, Spargo A, Hoyt M, Panni T, Viktrup L, Kim G, et al.
Headache . 2024 Jun; 64(7):796-809. PMID: 38898657
Objective: To describe treatment patterns and direct healthcare costs over 3 years following initiation of standard of care acute and preventive migraine medications in patients with migraine in the United...
8.
Effect size varies based on calculation method and may affect interpretation of treatment effect: an illustration using randomised clinical trials in osteoarthritis
Schnitzer T, Conaghan P, Berenbaum F, Abraham L, Cappelleri J, Bushmakin A, et al.
Adv Rheumatol . 2024 Apr; 64(1):31. PMID: 38650049
Background: To illustrate how (standardised) effect sizes (ES) vary based on calculation method and to provide considerations for improved reporting. Methods: Data from three trials of tanezumab in subjects with...
9.
Inter-Reader Consistency and Exclusionary Findings During Radiographic Screening for Phase 3 Trials of Tanezumab in Patients With Osteoarthritis
Guermazi A, Roemer F, Kompel A, Diaz L, Crema M, Brown M, et al.
Osteoarthr Imaging . 2024 Feb; 2(3-4). PMID: 38343426
Objective: Describe the radiograph-based screening program and frequencies of ineligibility in 3 large, international, randomized, double-blind, phase 3 studies of subcutaneous tanezumab in patients with osteoarthritis (OA). Design: Standardized bilateral...
10.
Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study
Varnado O, Vu M, Buysman E, Kim G, Allenback G, Hoyt M, et al.
Curr Med Res Opin . 2024 Feb; 40(4):635-646. PMID: 38334320
Objective: To describe long-term (24-month) treatment patterns of patients initiating galcanezumab versus standard of care (SOC) preventive migraine treatments including anticonvulsants, beta-blockers, antidepressants, and onabotulinumtoxinA using administrative claims data. Methods:...